Hikma and Sun Pharma enter into exclusive licensing agreement for ILUMYA

Hikma Pharmaceuticals PLC. (Hikma) and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) announced today that they have entered into an exclusive licensing and distribution agreement for ILUMYA, an innovative biologic product, for the Middle East and North Africa (MENA) region.

ILUMYA (tildrakizumab) is a USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Under the agreement, Hikma, the multinational pharmaceutical company, will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma,  the world's fourth largest specialty generic pharmaceutical company, will be responsible for product supply. The agreement’s term is 15 years from first sale with a two-year automatic renewal post the expiration of the agreement.

In comment, Mazen Darwazah, Hikma’s executive vice chairman and president of MENA said, “We are excited to partner with Sun Pharma and bring ILUMYA to our patients in MENA.ILUMYA™ is the first innovative monoclonal antibody product we add to our portfolio.”